1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation

1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation

Exam Focus: A comprehensive understanding of the jurisdictional separation between federal authorities (drug safety, efficacy review, patent ceiling prices, controlled substances) and provincial/territorial authorities (healthcare administration, hospital management, pharmacy practice acts, and public formulary coverage) is foundational for pharmacy practice and heavily tested on the PEBC Evaluating Examination.

---

The Architecture of Canadian Medicare

Canada's publicly funded universal healthcare system—known as Medicare—is not a centralized federal health system. Instead, it operates as an interlocking decentralized framework of thirteen distinct provincial and territorial single-payer health insurance plans.

Under the Constitution Act, 1867, provincial and territorial governments hold constitutional jurisdiction over the direct management, organization, and delivery of healthcare services to their populations. The federal government influences national healthcare policy through fiscal transfer payments—specifically the Canada Health Transfer (CHT)—and enforces national standards established under the Canada Health Act (1984).

+-------------------------------------------------------------------------+
|                     CANADIAN PHARMACEUTICAL LANDSCAPE                   |
+-------------------------------------------------------------------------+
|  1. HEALTH CANADA (HPFB)                                                |
|     Reviews Safety, Efficacy, Quality -> Issues NOC & 8-Digit DIN       |
|                                |                                        |
|                                v                                        |
|  2. PMPRB (Federal Quasi-Judicial Body)                                 |
|     Sets Maximum Non-Excessive Factory-Gate Ceiling Prices for Patented |
|                                |                                        |
|                                v                                        |
|  3. CANADIAN DRUG AGENCY / CADTH (Health Technology Assessment)         |
|     Evaluates Cost-Effectiveness & Issues Reimbursement Recommendations|
|                                |                                        |
|                                v                                        |
|  4. pan-CANADIAN PHARMACEUTICAL ALLIANCE (pCPA)                         |
|     Conducts Joint Price Negotiations on Behalf of Public Drug Plans    |
|                                |                                        |
|                                v                                        |
|  5. PROVINCIAL/TERRITORIAL PUBLIC FORMULARIES (e.g., ODB, RAMQ, BC)     |
|     Make Final Listing Decisions and Set Patient Reimbursement Criteria |
+-------------------------------------------------------------------------+

---

The Canada Health Act (1984): Five Foundational Principles

The Canada Health Act (CHA) is federal legislation establishing the statutory criteria and conditions that provincial and territorial health insurance plans must fulfill to receive their full cash contribution under the Canada Health Transfer. Failure to comply with these principles results in mandatory financial deductions from federal transfer funds.

The Five Statutory Principles

1. Public Administration:
   • The provincial health insurance plan must be administered and operated on a non-profit basis by a public authority accountable to the provincial government.
   • Private insurance companies cannot administer the public core health insurance plan.
2. Comprehensiveness:
   • The health insurance plan must cover all medically necessary services provided by hospitals, medical practitioners, and surgical dentists where permitted.
   • Crucial Pharmacy Distinction: Outpatient prescription medications dispensed in community pharmacies are not defined as mandatory insured services under the Canada Health Act. Inpatient hospital medications are fully covered, but outpatient pharmaceutical coverage has developed as a mixed system of provincial public drug programs, private employer-sponsored plans, and out-of-pocket payments.
3. Universality:
   • 100% of insured residents of a province or territory are entitled to the insured health services provided by the plan on uniform terms and conditions, without discrimination based on age, income, gender, or pre-existing medical conditions.
4. Portability:
   • Residents moving from one province to another remain covered by their originating home province during a waiting period of up to three (3) months before coverage transitions to the new host province.
   • Insured health services must also be covered when an insured resident temporarily travels outside their home province or abroad (reimbursed at the home province's fee schedule rate).
5. Accessibility:
   • Insured health services must be provided on uniform terms and conditions without financial or structural barriers.
   • Direct patient charges, user fees, or extra-billing by physicians and hospitals for medically necessary insured services are strictly prohibited.

---

Constitutional Division of Healthcare Responsibilities

The regulation of health products, practitioners, and healthcare delivery in Canada is divided between federal and provincial/territorial jurisdictions.

Federal Responsibilities

• Product Safety, Efficacy, and Quality: Regulating pharmaceuticals, biologics, medical devices, and natural health products through the Food and Drugs Act and Food and Drug Regulations.
• Controlled Substances: Regulating narcotics, controlled drugs, and targeted substances through the Controlled Drugs and Substances Act (CDSA).
• Patents and Price Ceilings: Administering pharmaceutical patents and regulating maximum non-excessive drug ceiling prices via the Patented Medicine Prices Review Board (PMPRB).
• Direct Healthcare for Designated Populations: Direct funding and delivery of healthcare and prescription benefits for federally covered populations:
  • First Nations and Inuit populations through the Non-Insured Health Benefits (NIHB) program.
  • Active members of the Canadian Armed Forces (CAF).
  • Eligible veterans through Veterans Affairs Canada (VAC).
  • Inmates in federal correctional institutions (sentences of 2 years or longer).
  • Eligible resettled refugees through the Interim Federal Health Program (IFHP).

Provincial and Territorial Responsibilities

• Healthcare Delivery: Financing, managing, and operating hospitals, long-term care homes, and community clinics.
• Professional Regulation: Regulating health professions (pharmacists, pharmacy technicians, physicians, nurses) through provincial legislation and regulatory colleges.
• Pharmacy Licensing and Practice: Enacting pharmacy acts, licensing and inspecting community and hospital pharmacy premises, and establishing clinical scopes of practice.
• Public Drug Formularies: Designing, funding, and administering provincial public drug benefit programs (e.g., Ontario Drug Benefit [ODB], BC PharmaCare, RAMQ in Quebec, Alberta Blue Cross public plans), setting eligibility criteria, deductibles, copayments, and benefit tiers.

---

Health Canada and the Federal Drug Review Pipeline

Health Canada is the federal department responsible for national public health. Within Health Canada, the Health Products and Food Branch (HPFB) regulates therapeutic products.

Market Authorization Process

1. Clinical Trial Application (CTA): Submitted to HPFB to authorize clinical trials (Phases I-III) in human subjects in Canada.
2. New Drug Submission (NDS): Submitted by brand manufacturers containing comprehensive preclinical, clinical safety, and efficacy data.
   • For generic drugs, an Abbreviated New Drug Submission (ANDS) is submitted, demonstrating pharmaceutical equivalence and bioequivalence to a Canadian Reference Product (CRP).
3. Notice of Compliance (NOC): Issued by HPFB when clinical data demonstrate that the therapeutic benefits outweigh the risks and manufacturing quality meets national standards.
4. Drug Identification Number (DIN): An 8-digit number assigned to each authorized drug product, uniquely identifying the manufacturer, active ingredient(s), dosage form, route of administration, and strength.

Post-Market Safety and Vanessa's Law

• MedEffect Canada: Health Canada's post-marketing surveillance and adverse reaction reporting program.
• Vanessa's Law (Protecting Canadians from Unsafe Drugs Act): Key legislative amendments to the Food and Drugs Act that:
  • Empower Health Canada to order mandatory drug recalls and compel product label changes.
  • Require pharmaceutical manufacturers to conduct post-market safety and efficacy studies.
  • Mandate that Canadian healthcare institutions (hospitals) report all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) to Health Canada within 30 calendar days.
• Risk Communications: Health Canada issues Dear Healthcare Professional Communications (DHPC), public advisories, and black-box warning updates for emerging drug safety hazards.

---

Health Technology Assessment & Reimbursement: CDA and pCPA

Market authorization by Health Canada (NOC and DIN) permits legal sale in Canada but does not ensure funding under provincial public drug formularies.

1. The Canadian Drug Agency (CDA / formerly CADTH)

The Canadian Drug Agency (CDA)—formerly the Canadian Agency for Drugs and Technologies in Health (CADTH)—is an independent, not-for-profit health technology assessment (HTA) agency funded by federal, provincial, and territorial governments.

• Reimbursement Reviews: Evaluates clinical efficacy, safety, and cost-effectiveness (cost-utility analyses) of new drugs compared to existing therapies.
• Listing Recommendations: Issues recommendations to participating federal, provincial, and territorial public drug plans (Quebec utilizes the Institut national d'excellence en sante et en services sociaux [INESSS]):
  • Reimburse: Add to public formulary without restrictions.
  • Reimburse with Clinical Criteria / Conditions: List conditional on cost-effectiveness thresholds or specific clinical criteria (the majority of positive recommendations).
  • Do Not Reimburse: Clinical benefit is unproven or cost is prohibitive relative to therapeutic gain.

2. pan-Canadian Pharmaceutical Alliance (pCPA)

Following a positive CDA recommendation, the pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint price and rebate negotiations with the manufacturer on behalf of public drug plans. When negotiations conclude successfully, a Letter of Intent (LOI) is signed, establishing baseline pricing terms for individual provincial public formularies.

---

Price Regulation: The PMPRB

The Patented Medicine Prices Review Board (PMPRB) is an independent, quasi-judicial federal agency established under the Patent Act.

• Consumer Protection Mandate: Ensures that prices charged by manufacturers for patented brand-name medicines sold in Canada are not excessive.
• Jurisdiction: Regulates the manufacturer's factory-gate wholesale price, not retail pharmacy markups or dispensing fees.
• Ceiling Price Benchmarking: Establishes the Maximum Allowable Price (MAP) by comparing Canadian prices against a basket of comparator OECD nations (the PMPRB11 basket, which includes Australia, France, Germany, the UK, and Sweden, while excluding the United States and Switzerland to prevent excessive price distortion).

---

Provincial Public Drug Benefit Formularies

Each province and territory maintains its own statutory formulary listing covered medications across specific tiers:

• General / Open Benefit: Automatically reimbursed for all eligible plan beneficiaries without prior authorization.
• Restricted / Limited Use (LU) / Specific Benefit: Requires specific clinical criteria or diagnostic codes documented on the prescription by the prescriber.
• Exceptional Access Program (EAP) / Exception Drug Status (EDS) / Special Authorization: Requires prior submission and individual clinical approval by the public plan before coverage is granted (typically reserved for high-cost biologics, second-line oncology agents, or specialty medications).